Efficient lung-targeted delivery of risedronate sodium/vitamin D3 conjugated PAMAM-G5 dendrimers for managing osteoporosis: Pharmacodynamics, molecular pathways and metabolomics considerations

pubmed: wnt1 2023-01-29


AIMS: This study aims at formulating combined delivery of Risedronate sodium (RIS) and Vitamin D3 (VITD3) for augmented therapeutic outcome against osteoporosis (OP) using deep lung targeted PAMAM-G5-NH(2) dendrimers to minimize RIS gastrointestinal side effects and enhance both drugs bioavailability through absorption from the alveoli directly to the blood.



From feeds:

Exome ยป pubmed: wnt1



Nihal Mohamed Elmahdy Elsayyad, Iman Gomaa, Mohamed A Salem, Reham Amer, Hanan M El-Laithy

Date tagged:

01/29/2023, 01:42

Date published:

09/29/2022, 06:00